CAN
Pharmaceuticals, Biotechnology & Life Sciences
Cann Group
- Short interest
- <0.01%
- −4.39 pp 30d
- as of 23 Oct 2026
- Reported shorts
- 262
- Shares on issue
- 1.661B
Cann Group (CAN) company profile
Profile, insiders and operations
Company
AI-generated research profile of Cann Group
Pharmaceuticals
Biotechnology
Medicinal Cannabis
ASX
Australian Company
Cann Group is an Australian pharmaceutical company focused on cultivating cannabis for medicinal and research purposes. They manufacture medicinal cannabis products, aiming to be a national benchmark for R&D and production processes. The company strives to improve the quality of life for patients through ethical leadership in the emerging medical cannabis industry.
Director trades
14 trades recorded
Who owns it
1 substantial holder disclosing 9.27%
Unclassified 9.27%
| Holder | Kind | Voting power | Change | As at | Notice |
|---|---|---|---|---|---|
| s Noble Investments Superannuation Fund Pty Ltd | Unclassified | 9.27% | Became substantial | 2026-01-03 |
From ASX substantial holding notices (5% or more), index ETF holdings files and super fund portfolio holdings disclosures. Holders' interests can overlap. How ownership is read.
CAN intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required